Format

Send to

Choose Destination
Clin Pharmacol Ther. 2014 Feb;95(2):179-88. doi: 10.1038/clpt.2013.170. Epub 2013 Aug 29.

Evaluation of various static and dynamic modeling methods to predict clinical CYP3A induction using in vitro CYP3A4 mRNA induction data.

Author information

1
Novartis, East Hanover, New Jersey, USA.
2
GlaxoSmithKline, King of Prussia, Pennsylvania, USA.
3
Pfizer, Groton, Connecticut, USA.
4
Merck Research Laboratories, West Point, Pennsylvania, USA.
5
AbbVie Inc, North Chicago, Illinois, USA.
6
Johnson & Johnson Pharmaceutical Research Institute, Raritan, New Jersey, USA.
7
Bristol-Myers Squibb, Wallingford, Connecticut, USA.
8
University of Washington, Seattle, Washington, USA.
9
US Food and Drug Administration, Silver Spring, Maryland, USA.

Abstract

Several drug-drug interaction (DDI) prediction models were evaluated for their ability to identify drugs with cytochrome P450 (CYP)3A induction liability based on in vitro mRNA data. The drug interaction magnitudes of CYP3A substrates from 28 clinical trials were predicted using (i) correlation approaches (ratio of the in vivo peak plasma concentration (Cmax) to in vitro half-maximal effective concentration (EC50); and relative induction score), (ii) a basic static model (calculated R3 value), (iii) a mechanistic static model (net effect), and (iv) mechanistic dynamic (physiologically based pharmacokinetic) modeling. All models performed with high fidelity and predicted few false negatives or false positives. The correlation approaches and basic static model resulted in no false negatives when total Cmax was incorporated; these models may be sufficient to conservatively identify clinical CYP3A induction liability. Mechanistic models that include CYP inactivation in addition to induction resulted in DDI predictions with less accuracy, likely due to an overprediction of the inactivation effect.

PMID:
23995268
DOI:
10.1038/clpt.2013.170
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center